What would you like to look for?
Site search
19 April 2023

ATANIS Biotech AG, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech investors. With the proceeds from the financing, ATANIS will accelerate its product development, scale its services for pharma/biotech customers, and implement its go-to-market strategy.

VISCHER acted as counsel to ATANIS Biotech AG in this transaction. The team consisted of Gian-Andrea Caprez and Sandro Bernet (both Corporate/M&A).